   
 
OncoNano Medicine Inc. 
181 Grand Avenue , Ste 225 
Southlake , Texas 7 6092 
 
 
Protocol and Protocol Amendments  
  
Title  A Phase 2, Single -Dose, Open -Label Study to 
Evaluate Diagnostic Performance and Safety of 
Pegsitacianine, An Intraoperative Fluorescence Imaging Agent for the Detection of Lung Malignancies, In Patients Undergoing Routine 
Surgery  
Study Drug  Pegsitacianine (ONM -100) 
Protocol Amendment 2.0  25 January 2022  
Original Protocol  31 August 2021  
 
 
 
  
Confidential   STUDY PROTOCOL  
A PHASE 2, SINGLE- DOSE, OPE N-LABEL STUDY TO EVALUATE DIAG NOSTIC 
PERFORMAN CE AN D SAFETY OF PEGSITACIAN INE, AN  INTRAOPERATIVE 
FLUORESCENCE IMAGIN G AGE NT FOR THE DETECTION OF LUN G MALIG NANCIES, 
IN PATIE NTS UN DERGOI NG ROUTINE SURGERY  
PROTOCOL NUMBER:  ON-1005  
Name of Drug: Pegsitacianine (ONM-100) 
Phase of Development: Phase 2 
Sponsor: OncoNano Medicine 
Sponsor Contact: 
Project Manager: 
Medical Monitor: 
Version: 2 
Date of Protocol: 25 Jan 2022 
Proprietary Notice: The concepts and information contained in this document 
or generated during the study are considered proprietary and may not be disclosed in whole or in part without the 
expressed, written consent of OncoNano. 
Compliance Statement: The study will be completed according to the guidelines of 
International Conference on Harmonisation Good Clinical Practice. Compliance with this standard provides public assurance that the rights, safety, and well-being of trial patients are protected, consistent with the principles that have their origin in the Declaration of Helsinki. 
OncoNano Medicine, Inc  
Study Protocol: O N-1005   Page 2 of 48 
Version 02 25 Jan 2022  Confidential  SIGNATURE PAGE  
 
 
 
PROTOCOL TITLE:  A Phase 2, single -dose, open -label study to evaluate diagnostic 
performance and safety of pegsitacianine, an intraoperative 
fluorescence imaging agent for the detection of lung malignancies , 
in patients undergoing routine surgery  
 
PROTOCOL NUMBER:  ON-1005   
 
 
 
 
 
 
 
 
 
VP, Head of Clinical Operations  Date 
 
 
INVESTIGATOR STATEMENT  
  
I agree to conduct the study as outlined in the protocol in accordance with accepted Good 
Clinical Practice, the guidelines and all applicable government regulations including 21 CFR 54.  
 
I have read and understand all sections of the protocol . 
 
 
 
 
 
 
<Principal Investigator‚Äôs Name>  
  Date 
  

OncoNano Medicine, Inc  
Study Protocol: O N-1005   Page 3 of 48 
Version 02 25 Jan 2022  Confidential   
REVISION HISTORY  
Version Number Date Summary of Changes 
1    31 Aug 2021  Original 
2 25 Jan 2022 ÔÇ∑ Updated the Medical Monitor 
ÔÇ∑ Removal of lab values from exclusion criteria 
ÔÇ∑ Updated Inclusion Criteria for clarification 
ÔÇ∑ Updated safety information for completed 1002 study  
ÔÇ∑ Removed hypothesis testing from sample size 
calculation 
ÔÇ∑ Included description of site personnel training and responsibilities 
ÔÇ∑ Updated Requirements for Part 2 enrollment 
ÔÇ∑ Updated Statistical analysis to account for correlation 
ÔÇ∑ Clarification of Pegsitacianine as a novel drug 
ÔÇ∑ Updated Intent to treat, safety, efficacy populations 
ÔÇ∑ Removal of the any additional investigational drug 
restriction 30 days prior 
ÔÇ∑ Updated definitions of parameters of Imaging Analysis 
   
   
   
   
   
   
   
   
 
  
OncoNano Medicine, Inc 
Study Protocol: O N-1005   Page 4 of 48 
Version 02 25 Jan 2022 Confidential TABLE OF CONTE NTS 
Signature Page ................................................................................................................................ 2 
Table Of Contents ........................................................................................................................... 4 Protocol Summary .......................................................................................................................... 7 Abbreviations ................................................................................................................................ 14 1. Introduction ................................................................................................................... 16 
1.1 Overview ....................................................................................................................... 16 
1.2 Pegsitacianine Clinical Trial Background .................................................................... 16 
1.3 Pharmacodynamics and Dose Selection ....................................................................... 18 
2. Study Objectives ........................................................................................................... 20 
2.1 Primary Objective ......................................................................................................... 20 
2.2 Secondary Objectives.................................................................................................... 20 
2.3 Exploratory Objectives ................................................................................................. 20 
3. Study Plan ..................................................................................................................... 20 
3.1 Overall Design .............................................................................................................. 20 
3.2 Imaging Assessments .................................................................................................... 21 
3.3 Safety Assessments ....................................................................................................... 22 
4. Study Drug Dosage and Administration ....................................................................... 22 
4.1 Prohibited Medications and Restrictions ...................................................................... 22 
4.2 Study Drug Description ................................................................................................ 22 
4.3 Study Drug Safety ......................................................................................................... 23 
4.4 Study Drug Packaging and Storage .............................................................................. 24 
4.5 Drug Accountability...................................................................................................... 25 
5. Subject Enrollment........................................................................................................ 25 
5.1 Inclusion Criteria .......................................................................................................... 25 
5.2 Exclusion Criteria ......................................................................................................... 26 
5.3 Randomization Procedures ........................................................................................... 26 
5.4 Blinding Procedures ...................................................................................................... 26 
5.5 Breaking the Blind ........................................................................................................ 26 
5.6 Subject Withdrawal ....................................................................................................... 26 
OncoNano Medicine, Inc 
Study Protocol: O N-1005   Page 5 of 48 
Version 02 25 Jan 2022 Confidential 5.6.1 Reasons for Withdrawal ................................................................................................ 26 
5.6.2 Handling of Withdrawals .............................................................................................. 27 
5.6.3 Replacements ................................................................................................................ 27 
5.6.4 Termination of Study .................................................................................................... 27 
6. Study Visits ................................................................................................................... 28 
6.1 Screening and Enrollment (Days ‚Äì30 to ‚Äì1) ................................................................. 28 
6.2 Pegsitacianine Administration (Day 0) ......................................................................... 28 
6.3 Surgery and Follow-up Visits ....................................................................................... 29 
6.4 Early Withdrawal Procedures ....................................................................................... 31 
6.5 Training ......................................................................................................................... 31 
7. Study assessments ......................................................................................................... 31 
7.1 Demographic Data/Medical History ............................................................................. 31 
7.2 Physical Examination.................................................................................................... 31 
7.3 Weight and Height ........................................................................................................ 31 
7.4 Vital Sign Measurements .............................................................................................. 31 
7.5 12-lead Electrocardiogram ............................................................................................ 32 
7.6 Clinical Laboratory Tests .............................................................................................. 32 
7.6.1 Pregnancy Tests ............................................................................................................ 32 
7.6.2 Laboratory Measurements ............................................................................................ 32 
8. Reporting Adverse Events ............................................................................................ 33 
8.1 Definitions..................................................................................................................... 33 
8.2 Adverse Event Reporting .............................................................................................. 34 
8.3 Assessment of Causality ............................................................................................... 34 
8.4 Assessment of Severity ................................................................................................. 35 
8.5 Serious Adverse Event Reporting ................................................................................. 36 
8.5.1 SAE Reporting Contact Information ............................................................................ 36 
9. Statistical Methods ........................................................................................................ 36 
9.1 Sample Size ................................................................................................................... 36 
9.2 Populations .................................................................................................................... 36 
9.3 Rate of Clinically Significant Events ............................................................................ 37 
OncoNano Medicine, Inc 
Study Protocol: O N-1005   Page 6 of 48 
Version 02 25 Jan 2022 Confidential 9.4 Imaging Analysis .......................................................................................................... 38 
9.5 Quantification of Fluorescence Intensity ...................................................................... 39 
9.6 Diagnostic Imaging Sensitivity Analyses ..................................................................... 39 
9.7 Safety Analysis ............................................................................................................. 39 
9.8 Interim Analyses ........................................................................................................... 40 
10. Data handling and quality assurance............................................................................. 40 
10.1 Data Security ................................................................................................................. 40 
10.2 Case Report Forms ........................................................................................................ 40 
10.3 Monitoring of the Study ................................................................................................ 40 
10.4 Inspection of Records ................................................................................................... 41 
10.5 Study Record Retention ................................................................................................ 41 
11. Administrative Considerations...................................................................................... 41 
11.1 Confidentiality .............................................................................................................. 41 
11.2 Institutional Review Board/Ethics Committee Approval ............................................. 42 
11.3 Modification of the Protocol ......................................................................................... 42 
11.4 Informed Consent.......................................................................................................... 42 
11.5 Protocol Violations and Deviations .............................................................................. 43 
11.6 Study Reporting Requirements ..................................................................................... 43 
11.7 Investigator Documentation .......................................................................................... 43 
11.8 Study Conduct ............................................................................................................... 44 
11.9 Publications ................................................................................................................... 44 
12. References ..................................................................................................................... 45 
13. Appendix 1: Schedule of Events ................................................................................... 46 
14. Appendix 2: FDA-Cleared NIR Imaging Devices ........................................................ 48 
14.1 NOVADAQ SPY Elite ................................................................................................. 48 
14.2 NOVADAQ SPY- PHI .................................................................................................. 48 
14.3 NOVADAQ PINPOINT ............................................................................................... 48 
14.4 da Vinci Firefly ............................................................................................................. 48 
14.5 Visionsense Iridium ...................................................................................................... 48 
 
OncoNano Medicine, Inc  
Study Protocol: O N-1005   Page 7 of 48 
Version 02 25 Jan 2022  Confidential  PROTOCOL SUMMARY  
Protocol 
Number ON-1005 
Title of Trial A Phase 2, single-dose, open-label study to evaluate diagnostic performance and 
safety of pegsitacianine, an intraoperative fluorescence imaging agent, for the detection of lung malignancies in patients undergoing routine surgery 
Phase of Clinical 
Trial Phase 2 
Indications Pegsitacianine is indicated as an imaging agent for intraoperative detection of lung 
malignancies in the thoracic cavity during routine surgical resection. Pegsitacianine 
is administered as a single dose  prior to surgery. 
Study Centers up to 5 centers  
Trial Objectives Primary Objective: 
The primary objective of this study is to determine if administration of 
pegsitacianine (  mg/kg) results in a clinically significant event at the level of the patient.   
Examples of clinically significant events include: 
1. The detection of disease that cannot be detected using standard procedures  
2. The detection of synchronous lesions 
3. The detection of positive surgical margins following primary tumor 
resection 
4. Tumor -negative standard of care (SOC) biopsy 
 
Secondary Objectives: 
Key secondary objectives are to evaluate the safety and toxicity of pegsitacianine. 
Additionally, the sensitivity, specificity, negative predictive values, and positive 
predictive values of the imaging agent will be calculated at the level of the individual specimens, including lymph nod es.  
Background Pegsitacianine is a novel intraoperative nanoparticle-based fluorescence imaging 
agent that was evaluated during  the first- in-human Phase 1 study (ON- 1001 ). ON-
1001 was completed in the Netherlands in patients with solid cancers undergoing 
surgical excision of their tumors. An additional Phase 1 study (ON- 1004) evaluating 
the pharmacokinetics in a healthy volunteer population has also been completed . 
Pegsitacianine was further evaluated in a completed Phase 2 study (ON-1002) in 
solid tumors. Pegsitacianine fluorescence is quenched when exposed to normal physiological pH but becomes activated following micellar disassembly in the acidic 
tumor microenvironment. Pegsitacianine was demonstrated to be well tolerated and showed no dose-limiting toxicities (DLT).  
Trial Design This Phase 2 study will be a n interventional, open-label, single arm trial where each 
patient is his/her own ‚Äúintrapatient‚Äù control. All patients will receive a single  
mg/kg dose of pegsitacianine  prior to 
standard of care (SOC) surgery.  It is recommended by the sponsor to administer 
prophylactic diphenhydramine before administration of pegsitacianine to decrease the possibility of an infusion-related reaction. The study will be conducted in two Parts. Part 1 will enroll patients undergoing minimally invasive procedures (i.e., video-assisted thorascopic surgery [VATS] or robotic surgery). Part 2 will be opened at the discretion of the Sponsor and include patients undergoing open 
thoracotomy for the removal of their disease .  Enrollment will be open first to Part 1 
with the opportunity to open Part 2 for enrollment following the demonstration of 
OncoNano Medicine, Inc  
Study Protocol: O N-1005   Page 8 of 48 
Version 02 25 Jan 2022  Confidential  satisfactory pegsitacianine sensitivity and specificity values of 70% or greater in 
Part 1. 
 
Patients will have a biopsy confirmed diagnosis, or a high clinical suspicion of a 
lung malignancy based on MRI, CT and/or PET imaging. A total of up to 40 patients will be enrolled in this trial across both parts. The sponsor reserves the right to 
perform an interim analysis following early enrollment (n ‚â§ 10 patients) to 
determine the feasibility and benefit of pegsitacianine as an adjunct to SOC 
surgery.  
 
Parts 1 and 2: 
 
The surgeon will attempt to perform their SOC resection of visible tumors. If the 
tumor is unable to be located u sing standard surgical approaches, an appropriate 
near-infrared (NIR) imaging device may be used to aid in localizing the primary 
tumor. Localization of the primary tumor using NIR imagi ng in conjunction with 
pathology confirmed presence of disease will be considered a clinically significant event.  
 
If the primary tumor is located using standard operative procedures, the tumor will be imaged using the NIR camera and removed as per standard of care (i.e., wedge, lobectomy, etc.). The primary resection will then be imaged (front, back and margins) on a piece of normal tissue within the surgical field at a distance from the specimen equal to the working distance of the camera system
. Inspection and 
imaging of the resection margins will be performed using the NIR camera system. If an area of suspicion is observed, images will be captured of the area, at the working distance of the camera away from the margin and documented for future correlati on 
to pathological findings. Similarly, the in situ  resection margin on the lung will be 
imaged for signs of residual fluorescence that may correspond to disease left behind. 
If found, images will be captured prior to the excision of the margin ( in situ ) and 
following its resection on a piece of normal tissue ( ex situ ). Resection of the 
suspicious or fluorescent margin is at the discretion of the surgeon. This procedure is to be repeated if additional SOC nodules are planned for resection. An identical approach will be followed for any SOC lymph nodes collected during the procedure. Lymph node imaging will occur prior to and following the removal of the suspected 
lymph nodes. 
 Once SOC surgical resection is complete, the surgeon will use the NIR camera system to evaluate the thoracic cavity (i.e., chest wall, contralateral lung, bronchi, 
etc.) for indications of residual fluorescence. If additional fluorescent foci are observed, the area may be resected, at the discretion of the surgeon, for pathological 
confirmation of disease. Similar to the imaging of margin resections, the suspected 
area will be imaged prior to removal ( in situ ) and following resection ( ex situ ) on a 
piece of normal tissue within the thoracic cavity. Additional fluorescent lymph nodes, detected during the evaluation of the thoracic cavity, may also be collected and imaged both in situ  and ex situ  prior to being evaluated in pathology. 
 
Collected surgical specimens will be documented by the clinical research 
coordinator, as dictated by the surgeon in the provided Imaging Workbook. The fluorescence status of each specimen will be assessed and called out by the surgeon 
(fluorescent or not fluorescent), and similarly documented in the workbook. All 
samples will be sent to pathology for routine analysis. To determine the performance 
OncoNano Medicine, Inc  
Study Protocol: O N-1005   Page 10 of 48 
Version 02 25 Jan 2022  Confidential  8. Pregnant or lactating 
9. Taking or plan to take medications with known hepatoxicity  
10. Any other significant medical condition the investigator deems 
inappropriate for the trial including any medical or psychiatric conditions 
that would impair informed consent 
Sample Size N=40  
 
Up to 40 patients will be enrolled in this study. No set allocation of patients to Part 1 
and Part 2 will be implemented, rather Part 2 will be opened at the discretion of the 
sponsor following the demonstration of satisfactory pegsitacianine sensitivity and specificity values of 70% or greater in Part 1. The sponsor reserves the right to 
perform an interim analysis following early enrollment (i.e., n ‚â§ 10 patients) to 
determine the feasibility and benefit of pegsitacianine as an adjunct to standard 
of care lung malignancy resection.  
Statistical 
Analysis The quotient of patients with a CSE over the total number of patients undergoing 
surgery who received any dose of the study drug, and had sufficient imaging data 
(minimum of 1 collected image). Sensitivity and specificity will be determined at 
the specimen level based on correlated fluorescence status and pathological outcome.   Pegsitacianine performance data will be evaluated in toto , as well as separately if 
Part 2 of the study is opened to enrollment. Part 1 and Part 2 data will be evaluated independently to assess performance when using different imaging systems within 
their respective procedure (i.e., minimally invasive vs. open).  
Schedule of 
Events Screening (Day - 30 to -1)   
 
Before the study doctor can administer pegsitacianine, he/she must ensure that it is 
safe for the patient to be in the study vis-√†-vis information that is already known 
about pegsitacianine. After the patient has agreed to be in the study and signed the 
informed consent form, the study team will perform the following procedures (information collected as part of standard of care within a reasonable timeframe that meet the presurgical requirements of the institution are also acceptable):  
ÔÇ∑ Collect demographic data 
ÔÇ∑ Record their complete medical history 
ÔÇ∑ Perform a complete physical examination 
ÔÇ∑ Measure their weight and height and calculate a body mass index (BMI) to estimate body fat tissue 
ÔÇ∑ Record vital signs (temperature, heart rate, blood pressure, and 
respirations) 
ÔÇ∑ Obtain a blood sample for routine laboratory tests, including a 
pregnancy test for females who can become pregnant 
ÔÇ∑ Record medications they have been taking, including prescription, over- the-counter, and herbal medications 
ÔÇ∑ Determine Karnofsky Performance Status (to assess the ability to perform ordinary daily tasks) 
ÔÇ∑ Confirm that the patient has met all the study criteria to participate 
 
Day 0 (Pegsitacianine administration) 
 
Predose procedures 
OncoNano Medicine, Inc  
Study Protocol: O N-1005   Page 12 of 48 
Version 02 25 Jan 2022  Confidential  Once the patient is under anesthesia, some procedures will occur that would not 
normally be part of surgery if the patient were not in this study. The SOC surgical procedures will be allowed to continue with the addition of the steps listed below. 
ÔÇ∑ If the primary tumor is not visually apparent using standard approaches, the NIR camera may be used to help locate and guide the resection of the primary tumor 
ÔÇ∑ If the primary tumor is apparent under standard conditions, the suspected area will be imaged using the intraoperative camera prior to excision, and on a section of normal tissue at a distance 
equal to the working distance of the camera following excision 
ÔÇ∑ Following the primary tumor resection, margins (both on th e 
excised primary and the remaining lung) will be examined using 
NIR in an effort to detect the presence of a possible positive 
margin 
ÔÇ∑ Any SOC lymph nodes that are to be collected will be imaged prior to, and following excision in a manner identical to tha t 
performed on the primary tumor specimen 
ÔÇ∑ Once the SOC primary tumor and lymph node resection is complete, the surgeon will examine the thoracic cavity with the intraoperative NIR camera in search of additional fluorescent 
disease that was missed during SOC, or additional fluorescent 
lymph nodes 
ÔÇ∑ Additional fluorescent lesions will be imaged prior to excision, removed, and then imaged on a section of normal tissue in a manner analogous to the SOC specimens.  
Day of Discharge  
ÔÇ∑ Record the patient‚Äôs vital signs  
ÔÇ∑ Perform a physical examination  
ÔÇ∑ Discuss new or unexpected changes in they are feeling  
ÔÇ∑ Obtain blood samples for routine laboratory tests 
ÔÇ∑ Record all medications being tak en, including prescription, over-
the-counter, and herbal medications 
ÔÇ∑ Discuss any new or unexpected changes  
ÔÇ∑ Record any AEs 
 Day 21 (¬±10 days) after dosing 
ÔÇ∑ Record the patient‚Äôs vital signs  
ÔÇ∑ Perform 12-lead ECG to monitor heart activity 
ÔÇ∑ Perform a physical examination  
ÔÇ∑ Discuss new or unexpected changes in how they are feeling  
ÔÇ∑ Obtain blood samples for routine laboratory tests, including a pregnancy test for females who can become pregnant 
ÔÇ∑ Record all medications being tak en, including prescription, over-
the-counter, and herbal medications 
ÔÇ∑ Discuss any new or unexpected changes  
ÔÇ∑ Record any AEs 
Training  Extensive training will be provided to all study staff. Initial training will occur at the 
Site Initiation Visit, followed by on-site training that will take place during the 
initial surgical procedures with Sponsor Representatives present in the operating 
room during the procedures. Sponsor Representatives will ensure all study personnel 
OncoNano Medicine, Inc  
Study Protocol: O N-1005   Page 13 of 48 
Version 02 25 Jan 2022  Confidential   
  are adequately trained and follow identical procedures to preserve the integrity of 
the collected data without providing input on the selection of specimens or their fluor escent status, these tasks are are the sole responsibility of the operating 
surgeon. Additional retraining may take place if necessary throughout the course of the study. Training will include a review of protocol procedures, NIR camera operating instructions, documentation of specimens and their fluorescence status, and upload of source documentation. All training will be documented and stored within the Trial Master File.  
OncoNano Medicine, Inc  
Study Protocol: O N-1005   Page 14 of 48 
Version 02 25 Jan 2022  Confidential  ABBREVIATIO NS 
ABBREVIATIO N TERM 
AE Adverse Event 
ALT  
ANOVA  Alanine Aminotransferase 
Analysis of Variance 
AST 
BMI  Aspartate Aminotransferase 
Body Mass Index 
BUN Blood Urea Nitrogen 
CFR  Code of Federal Regulations 
CSE 
CT 
CV 
D5W 
DoH 
ECG Clinically Significant Event 
Computed Tomography 
Curriculum Vitae 
5% Dextrose in water Declaration of Helsinki   
Electrocardiogram 
eCRF  Electronic Case Report Form 
FDA United States Food and Drug Administration 
HNSCC 
ICG Head and Neck Squamous Cell Carcinoma  
Indocyanine Green 
ICH International Conference on Harmonisation 
IRB 
IV Institutional Review Board 
Intravenous 
MFI 
MRI 
NIR 
NPV 
PEG 
PET 
PK Mean Fluorescence Intensity 
Magnetic Resonance Imaging 
Near -infrared 
Negative Predictive Value 
Polyethylene Glycol 
Positron Emission Tomography 
Pharmacokinetics 
PMMA 
PPV 
ROC 
SAE Polymethylmethacrylate 
Positive Predictive Value 
Receiver Operating Characteristic 
Serious Adverse Event  
SBR  Specimen- to-Background Ratio  
SOC Standard of C are 
SUSAR Suspected Unexpected Serious Adverse Reaction 
SWI 
TBR  Sterile Water for Injection  
Tumor- to-Background Ratio 
OncoNano Medicine, Inc  
Study Protocol: O N-1005   Page 15 of 48 
Version 02 25 Jan 2022  Confidential  ABBREVIATIO N TERM 
TEAE 
VATS 
WMA  Treatment-Emergent Adverse Event 
Video-Assisted Thorascopic Surgery 
World Medical Association  
 
  
OncoNano Medicine, Inc  
Study Protocol: O N-1005   Page 27 of 48 
Version 02 25 Jan 2022  Confidential  discretion and after approval by OncoNano‚Äôs  medical  monitor.  Justification fo r this 
decision should be clearly documented in source documents.  
ÔÇ∑ The subject becomes noncompliant or becomes uncooperative in returning for the 
scheduled study visits.  
ÔÇ∑ The subject requests withdrawal for any reason.  
The clinical study report will include reasons for subject withdrawals as well as details relevant 
to the subject withdrawal.  
5.6.2 Handling of Withdrawals  
If a subject withdraws prematurely from the study after receiving the study drug , study staff 
should make every effort to perform the Day 21 ( ¬±10 days) assessments. The reason for subject 
withdrawal must be documented in the e CRF . 
If a subject withdraws from the study because of an AE (clinical  or laboratory), the subject will 
be asked to return to the clinic for, at a minimum, the evaluations sc heduled. If the AE has still 
not resolved, additional follow -up will be performed as appropriate and documented in the 
subject‚Äôs medical records. As a minimum requirement, AEs should  be followed for 30  days after 
receipt of the subject‚Äôs last dose of study  drug, until resolution , or when judged to be stable for 
30 days . 
If a subject is lost to follow -up, 3 attempts (i.e., 2 phone calls, then 1 registered letter) to contact 
the subject will be made and documented in the subject‚Äôs medical records.  
5.6.3 Replacement s 
Withdrawn patients  may be replaced  at the discretion of the sponsor.   
5.6.4 Termination of Study  
If, in the opinion of the investigator, the clinical observations in the study suggest that it may be 
unwise to continue, the investigator may terminate the study  after consultation with OncoNano 
Medicine. A written statement fully documenting the reasons for such a termination will be 
provided to OncoNano Medicine. In addition, OncoNano Medicine reserves the right to 
discontinue the study at any time for any reaso n. Such a termination must be implemented by the 
investigator, if instructed to do so by OncoNano Medicine, in a time frame that is compatible 
with patients‚Äô well -being.  
If the study is terminated, all patients  will undergo a complete follow -up examination . Any 
clinically relevant findings, including clinically significant laboratory values and AEs, will be 
followed until resolution, stabilization for 30 days, or until the end of the study  (the last study 
evaluation for the last subject), whichever occurs f irst. 
OncoNano Medicine, Inc  
Study Protocol: O N-1005   Page 29 of 48 
Version 02 25 Jan 2022  Confidential  Dosing and postdose procedures  
Procedures during and after dosing of pegsitacianine  are summarized below:  
ÔÇ∑ Dosing of pegsitacianine  will be administered 
, length of infusion and overall volu me will depend on the assigned dose 
and the patient‚Äôs body weight.  
ÔÇ∑ The following postdose assessments and procedures will occur after infusion of 
the study drug has been completed:  
o Record the patient‚Äôs vital signs immediately after the infusion and 
30 minutes afterward  
o Discuss any new or unexpected changes in how the patient is feeling  
o Record any AEs  
o Record all medications they are taking, including prescription, over-the-
counter , and herbal medications  
6.3 Surgery and Follow -up Visits  
Procedures at the time of surgery  
 
The following procedures will be performed on the day of surgery (before administration of 
anesthesia and before surgery : 
 
ÔÇ∑ Record the patient‚Äôs vital signs  
ÔÇ∑ Obtain blood for routine laboratory tests  
ÔÇ∑ Record all med ications being taking, including prescription, over-the-counter , and 
herbal medications  
ÔÇ∑ Discuss with the patient any new or unexpected changes they are feeling .  
ÔÇ∑ Record any AEs.  
 
Once the patient is under anesthesia, some procedures will occur that would not normally be part 
of surgery if the patient were not in this study. The SOC surgical procedures will be allowed to 
continue with the addition of the imaging steps listed below.  
 
ÔÇ∑ If the primary tumor is not visually apparent using standard approaches, th e NIR 
camera may be used to help locate and guid e the resection of the primary tumor . 
o The primary tumor should be imaged prior to excision and following excision 
on a piece of normal tissue from a distance equal to the operating distance of 
the camera .  
ÔÇ∑ If the primary tumor is apparent under standard conditions, it will be imaged prior 
to resection. Additionally, the  resected  tissue will be imaged using the 
OncoNano Medicine, Inc  
Study Protocol: O N-1005   Page 30 of 48 
Version 02 25 Jan 2022  Confidential  intraoperative camera on a section of normal tissue at a distance equal to the 
operating distance of the camera  
ÔÇ∑ Following the primary tumor resection, margins (both on the excised primary and 
the affected lung) will be examined using NIR in an effort to detect residual 
disease  
ÔÇ∑ All SOC lymph nodes to be collected during the operative procedure will be 
imag ed prior to and following excision in a manner identical to the procedures 
used for imaging the primary resection  
ÔÇ∑ Once the SOC primary tumor resection is complete, the surgeon will examine the 
thoracic cavity with the intraoperative NIR camera in search of  additional 
fluorescent disease , or lymph nodes  that w ere missed during SOC  
ÔÇ∑ Additional fluorescent lesions , or lymph nodes  will be imaged prior to excision , 
removed and imaged on a section of normal tissue in a manner analogous to the 
SOC specimens.  
ÔÇ∑ For all resected specimens (including SOC primary tumor, margins, SOC lymph 
nodes and additional missed disease), fluorescence status and specimen name will 
be called out by the surgeon for documentation by the clinical research 
coordinator in the provided Ima ging Workbook  
 
Day of Discharge  
ÔÇ∑ Record the patient‚Äôs vital signs  
ÔÇ∑ Perform a physical examination  
ÔÇ∑ Obtain blood samples for routine laboratory tests  
ÔÇ∑ Record all medications being taking, including prescription, over -the-counter, and 
herbal medications  
ÔÇ∑ Discuss any new or unexpected changes they are feeling .  
ÔÇ∑ Record any AEs.  
 
Day 21 (¬±10 days) after dosing  
ÔÇ∑ Record the patient‚Äôs vital signs  
ÔÇ∑ Perform 12 -lead ECG to monitor  heart activity  
ÔÇ∑ Perform a physical examination  
ÔÇ∑ Obtain blood samples for routine laboratory tests, including a pregnancy test for 
females who can become  pregnant  
ÔÇ∑ Record all medications being taking, including prescription, over -the-counter, and 
herbal medications  
ÔÇ∑ Discuss any new or unexpected changes th ey are feeling .  
OncoNano Medicine, Inc  
Study Protocol: O N-1005   Page 31 of 48 
Version 02 25 Jan 2022  Confidential  ÔÇ∑ Record any AEs  
6.4 Early Withdrawal Procedures  
If a subject is withdrawn from the study before study completion, all procedures scheduled for 
the final visit (Day 21 ¬±10 days) should be performed if possible.  
6.5 Training  
Extensive training will b e provided to all study staff. Initial training will occur at the Site 
Initiation Visit, followed by on -site training that will take place  during the initial surgical 
procedures with Sponsor Representatives present  in the operating room during the procedur es. 
Sponsor Representatives will ensure all study personnel are adequately  trained and follow 
identical procedures to preserve the integrity of the collected data  without providing input on the 
selection  of specimens or their fluorescent status, these task s are are the sole responsibility of the 
operating surgeon . Additional retraining may take place if necessary throughout the course of the 
study.  Training will include a review of protocol procedures, NIR camera operating instructions, 
documentation of spe cimens and their fluorescence status,  and upload of source documentation.  
All training will be documented and stored within the Trial Master File.  
 
7.STUDY ASSESSME NTS  
7.1 Demographic Data/Medical History  
Demographic data and a complete medical history (includ ing drug, alcohol, and tobacco use, as 
well as current use of herbal supplements and multivitamins) will be obtained at Screening . 
7.2 Physical Examination  
A complete physical examination will be performed at Screening, Day of Discharge and on 
Day 21. The complete physical examination may include the following organ or body system 
assessments: skin ; head ; eyes; ears; nose; throat; thyroid; neurological; chest and lungs; 
cardiovascular; abdomen (liver and spleen); lymph nodes; musculoskeletal ; and extrem ities.   
7.3 Weight and Height  
Body weight (kg) and height (m) will be measured at Screening and weight will again be 
collected on Day 0 prior to dosing. The subject‚Äôs body mass index (BMI) will be calculated at 
Screening using the following formula:  
ùêµùëÄùêº= ùëäùëíùëñùëî‚Ñéùë° (ùëòùëî)
(ùêªùëíùëñùëî‚Ñéùë° [ùëö])2 
7.4 Vital Sign Measurements  
Vital sign measurements ( systolic and diastolic blood pressure, pulse, respiratory rate, and 
temperature ) will be obtained at Screening, Day 0 (Pre/Post dose), Day of Surgery, Day of 
Discharge and Day 21. 
Temperature will be documented  in degrees Celsius . 
OncoNano Medicine, Inc  
Study Protocol: O N-1005   Page 32 of 48 
Version 02 25 Jan 2022  Confidential  Blood pressure and pulse will be measured after  a resting period of at least 5 minutes  in the 
supine position with a standard mercury sphygmomanometer or an automated oscillometric 
blood pressure m onitor.  
7.5 12-lead Electrocardiogram  
A standard safety 12-lead ECG will be conducted on Day  0 (Pre -Dose) and on Day  21. 
Additional ECGs may be performed at the discretion of the investigator. The investigator or 
designee will be responsible for reviewing the ECG to assess whether the ECG is within the 
reference limits and to determine the clinical significance of the resu lts. These assessments will 
be recorded in the eCRF . 
7.6 Clinical Laboratory Tests  
Clinical laboratory tests (hematology and serum chemistry) will be performed by a Local and/or 
Central Laboratory . Blood samples will be collected at Screening, on Day 0, Day of Surgery, 
Day of Discharge and Day 21.  
7.6.1 Pregnancy Tests  
For female patients , a serum sample  or urine dipstick  will be collected for  the pregnancy test ( ÔÅ¢-
human chorionic gonadotropin) at Screening and blood samples will be collec ted for p regnancy 
tests on Day  0, and on Day  21. N egative pregnancy test result s will be required  for patients  to 
enroll and continue study participation . 
7.6.2 Laboratory Measurements  
Blood hematology and serum chemistry tests may be performed using the standar d panel of each 
institution  (it is not necessary to add analytes if not part of standard panel unless 
ordered/recommended by treating physician) . The following clinical laboratory parameters are 
an example of what is to be collected : 
OncoNano Medicine, Inc  
Study Protocol: O N-1005   Page 33 of 48 
Version 02 25 Jan 2022  Confidential  Clinical Chemistry  Hem atology 
Total protein Hemoglobin 
Albumin Hematocrit 
Blood urea nitrogen (BUN)  Erythrocyte count (red blood cells) 
Calcium (total and ionized) Differential leukocytes  
Creatinine Platelet count 
Creatine kinase Total leukocytes (white blood cells) 
Chloride  
Total bilirubin  
Alkaline phosphatase  
Glucose  
Sodium  
Potassium  
Inorganic phosphate  
Lactate dehydrogenase  
Total Cholesterol  
Gamma-glutamyl transferase  
Alanine aminotransferase (ALT)  
Aspartate aminotransferase (AST)  
 
8. REPORTIN G ADVERSE EV ENTS  
All adverse events ( AEs) will be recorded in the eCRF, whether they are observed by the 
investigator, reported by the subject, observed from laboratory findings, or collected by other 
means.  Adverse events will be monitored beginni ng on Day  0, following pegsitacianine 
administration, through the end of the study (Day 28). Adverse events will be graded by the 
Investigator using a numerical score according to the defined National Cancer Institute Common 
Terminology Criteria for Advers e Events (NCI CTCAE) Version 5.0 (2017).  
8.1 Definitions  
The investigator is responsible for reporting all AEs that are observed or reported during the 
study, regardless of their relationship to study drug or their clinical significance.  
An AE is defined as an y untoward medical occurrence in a subject enrolled into this study 
regardless of its causal relationship to study treatment. Patients  will be instructed to contact the 
principal investigator if any symptoms develop.  
A treatment -emergent AE  (TEAE) is defined as any event not present before the first exposure to 
the study drug or any event already present that worsens in either intensity or frequency 
following the first exposure to the study drug.  
All AEs that occur beginning on Day 0  must be reporte d in detail in the eCRF and followed to 
satisfactory resolution or until the principal investigator deems the event to be chron ic or the 
OncoNano Medicine, Inc  
Study Protocol: O N-1005   Page 34 of 48 
Version 02 25 Jan 2022  Confidential  subject to be stable. The description of the AE will include the onset date, duration, date of 
resolution, severity, se riousness, etiology, and the likelihood of relationship of the AE to study 
drug. 
A serious adverse event (SAE) is defined as any event that results in any of the following 
outcomes:  
ÔÇ∑ Results in death  
ÔÇ∑ Is life threatening, i .e., the subject was, in the opinio n of the investigator, at risk 
of death at the time of the event; it does not refer to an event that, hypothetically, 
might have caused death if it had occurred in a more severe form  
ÔÇ∑ Requires inpatient hospitalization or prolongs existing hospitalization  
ÔÇ∑ Results in persistent or significant disability and/or incapacity  
ÔÇ∑ Is a congenital anomaly/birth defect  
ÔÇ∑ Is an important medical event  
 
Important medical events that may not result in death, be life threatening, or require 
hospitalization may be considered an  SAE when , based upon appropriate medical judgment, they 
may jeopardize the subject and may require medical or surgical intervention to prevent one of the 
outcomes listed in this definition. Examples of such medical events include allergic 
bronchospasm req uiring intensive treatment in an emergency room or at home, blood dyscrasias, 
convulsions that do not result in inpatient hospitalization, or the development of drug 
dependency or drug abuse.  
8.2 Adverse Event Reporting  
All AEs reported  or observed during the  study will be recorded in the eCRF. Information to be 
collected includes drug treatment, dosage, type of event, time of onset, investigator -specified 
assessment of severity and relationship to study drug, time of resolution of the event, 
seriousness, any required treatment or evaluations, and outcome. Adverse events resulting from 
concurrent illnesses, reactions to concurrent illnesses, reactions to concurrent medications, or 
progression of disease states must also be reported. All AEs will be followed to adequate 
resolution.  
Any medical condition that is present at the time that the subject is screened but does not 
deteriorate should not be reported as an AE. However, if the condition deteriorates at any time 
during the study  after the first exposure to s tudy drug , it should be recorded as an AE.  
8.3 Assessment of Causality  
The investigator‚Äôs assessment of an AE's relationship to study drug is part of the documentation 
process, but it is not a factor in determining what is or is not reported in the study. If t here is any 
doubt as to whether a clinical observation is an AE, the event should be reported.  
OncoNano Medicine, Inc  
Study Protocol: O N-1005   Page 35 of 48 
Version 02 25 Jan 2022  Confidential  The relationship or association of the study drug  in causing or contributing to the AE will  be 
characterized using the following classification and criteria:  
ÔÇ∑ Unrelated : This relationship suggests that there is no association between the study drug 
and the reported event.  
ÔÇ∑ Unlikely : This relationship suggests the temporal association between the AE and the study 
drug is such that the study drug is not likely to have  any reasonable association with the 
AE. 
ÔÇ∑ Possible : This relationship suggests that treatment with the study drug caused or 
contributed to the AE, i .e., the event follows  a reasonable temporal sequence from the 
time of study drug administration and/or follo ws a known response pattern to the study 
drug, but could also have been produced by other factors.  
ÔÇ∑ Probable : This relationship suggests that a reasonable temporal sequence of the event 
with study drug administration exists and, based on the known pharmacol ogical action of 
the drug, known or previously reported adverse reactions to the drug or class of drugs, or 
judgment based on the investigator‚Äôs clinical experience, the association of the event with 
the study drug seems likely.  
ÔÇ∑ Definite : This relationship  suggests that a definite causal relationship exists between the 
study drug administration and the AE, and other conditions (concurrent illness, 
progression/expression of disease state, or concurrent medication reaction) do not appear 
to explain the event.  
8.4 Assessment of Severity  
The intensity of the AE will be rated according to CTCAE criteria (Version 5.0) ranging from 
Grade 1 to Grade 5. A brief explanation of the grading is provided below : 
ÔÇ∑ Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; 
intervention not indicated  
ÔÇ∑ Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age - 
appropriate instrumental  activities of daily living  (ADL ) 
o Instrumental ADL refers to preparing meals, shopping fo r groceries or clothes, 
using the telephone, managing money, etc.  
ÔÇ∑ Grade 3 Severe or medically significant but not immediately life -threatening;  
hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care 
ADL  
o Self-care ADL r efers to bathing, dressing and undressing, feeding self, using the 
toilet, taking medications, and not bedridden  
ÔÇ∑ Grade 4 Life-threatening consequences; urgent intervention indicated.  
ÔÇ∑ Grade 5 Death related to AE.  
 
OncoNano Medicine, Inc  
Study Protocol: O N-1005   Page 37 of 48 
Version 02 25 Jan 2022  Confidential  9.3 Rate of Clinically Significant Events  
Determining the rate  of clinically significant event s (CSE) detected by pegsitacianine  at the 
subject -level is the primary objective of this study . CSEs will include pegsitacianine detection of 
primary tumors otherwise undetectable using SOC procedures, detection of occult disease not 
otherwise known by the surgeon to exist, the detection o f a positive surgical margin, and 
accurate identification of tumor negative SOC biopsies. A list of CSEs and their definitions is 
provided below.  
 
ÔÇ∑ Detection of Synchronous  Disease  ‚Äì identification of tumor -containing tissue  due to 
pegsitacianine  fluorescen ce, confirmed via histopathological analysis, that otherwise 
went undetected during pre -operative imaging (PET , CT, MRI) or by the surgeon during 
SOC surgery.  
o This occurs when a specimen that comes from the thoracic cavity or lymph nodes, 
is (1) collected via fluorescence and (2) is pathologically -confirmed as a tumor. 
Note that any specimen collected from the thoracic cavity following SOC  will be 
considered to be collected by fluorescence .  
 
ÔÇ∑ Detection of Positive Surgical Margin  ‚Äì following the completion of SOC surgery, the 
surgical fields  will be examined for residual fluorescence. Detection of a positive surgical 
margin would be those specimens collected as a result of residual pegsitacianine  
fluorescence following the completion of SOC surgery that retu rn a histologically 
positive for tumor outcome.  
o when a margin specimen (either from the primary tumor or a lung resection 
margin) (1) is collected via fluorescence and (2) is pathologically -confirmed as a 
tumor. Note that any lung resection margin collect ed will be considered to be 
collected by fluorescence.  
 
ÔÇ∑ Identification/Localization of the Primary Tumor  ‚Äì during SOC surgery, the surgeon will 
examine the affected lung to locate the primary tumor. If the primary tumor is not 
visually apparent using stan dard imaging methods the surgeon may use the NIR imaging 
device to aid in localization. If the NIR imaging identifies and/or locates the primary 
tumor, which was undetectable using SOC approaches, this will be deemed a CSE.  
o This occurs when the primary tum or is not located using SOC approaches, and is 
instead identified using NIR imaging.  
 
ÔÇ∑ Tumor Negative SOC Biopsies  ‚Äì during SOC surgery, the surgeon will collect tissue 
specimens that are suspicious for disease. If those samples do not demonstrate 
pegsitac ianine  fluorescence and are found to be devoid of tumor pathologically, those 
specimens would be included as a tumor negative SOC biopsy.  
o This occurs when any SOC sample (primary tumor, additional SOC specimen, or 
lymph node) that is collected is found to be negative for tumor, and did not fluoresce 
during ex situ imaging.  
OncoNano Medicine, Inc  
Study Protocol: O N-1005   Page 38 of 48 
Version 02 25 Jan 2022  Confidential   
The number and proportion (with corresponding two -sided exact 95% c onfidence intervals) of 
subjects with any CSE will be reported.  
 
9.4 Imaging  Analysis  
Diagnostic  performance of pegsitacianine  will be assessed at the level of the specimen by 
calculating  the ex situ sensitivity , specificity, PPV, and NPV  of pegsitacianine  in detecting tumor 
containing tissue . The ex situ  fluorescence status of collected SOC and pegsitacianine  guided 
specimens will be compared to the histological analyses of the collected specimens  (which is used 
to determine each sample‚Äôs status as true/fal se positive/negative) . For determining these operating 
characteristics, consider the following definitions:  
ÔÇ∑ False positive  is defined as ‚Äúfluorescence was observed on the specimen but the specimen 
was not found to have tumor via histological analysis‚Äù.  
ÔÇ∑ False negative  is defined as ‚Äúno fluorescence was observed on the specimen but the 
specimen was found to have tumor via histological analysis‚Äù.  
ÔÇ∑ True positive  is defined as ‚Äúfluorescence was observed on the specimen and the specimen 
was found to have tumor via  histological analysis‚Äù.  
ÔÇ∑ True negative  is defined as ‚Äúno fluorescence was observed on the specimen and the 
specimen was found not to have tumor via histological analysis‚Äù.  
The number of specimens in each category (each combination of true/false positive/ne gative), 
along with the true/false positive/negative rates (and corresponding exact two -sided 95% 
confidence intervals) will be reported. These rates will be used to determine pegsitacianine‚Äôs tumor 
detection  sensitivity , specificity, PPV, and NPV  using  the following equations:  
        
ùë∫ùíÜùíèùíîùíäùíïùíäùíóùíäùíïùíö =# ùëúùëì ùëáùëüùë¢ùëí ùëÉùëúùë†ùëñùë°ùëñùë£ùëí ùëÜùëùùëíùëêùëñùëöùëíùëõùë†
# ùëúùëì ùëáùëüùë¢ùëí ùëÉùëúùë†ùëñùë°ùëñùë£ùëí ùëÜùëùùëíùëêùëñùëöùëíùëõùë† +# ùëúùëìùêπùëéùëôùë†ùëí ùëÅùëíùëîùëéùë°ùëñùë£ùëí  ùëÜùëùùëíùëêùëñùëöùëíùëõùë† 
 
ùë∫ùíëùíÜùíÑùíäùíáùíäùíÑùíäùíïùíö =#ùëúùëì ùëáùëüùë¢ùëí ùëÅùëíùëîùëéùë°ùëñùë£ùëí ùëÜùëùùëíùëêùëñùëöùëíùëõùë†
# ùëúùëì ùëáùëüùë¢ùëí ùëÅùëíùëîùëéùë°ùëñùë£ùëí  ùëÜùëùùëíùëêùëñùëöùëíùëõùë† +# ùëúùëìùêπùëéùëôùë†ùëí ùëÉùëúùë†ùëñùë°ùëñùë£ùëí ùëÜùëùùëíùëêùëñùëöùëíùëõùë†   
 
ùë∑ùë∑ùëΩ=# ùëúùëì ùëáùëüùë¢ùëí ùëÉùëúùë†ùëñùë°ùëñùë£ùëí ùëÜùëùùëíùëêùëñùëöùëíùëõùë†
# ùëúùëì ùëáùëüùë¢ùëí ùëÉùëúùë†ùëñùë°ùëñùë£ùëí ùëÜùëùùëíùëêùëñùëöùëíùëõùë† +# ùëúùëì ùêπùëéùëôùë†ùëí ùëÉùëúùë†ùëñùë°ùëñùë£ùëí ùëÜùëùùëíùëêùëñùëöùëíùëõùë†   
 
ùëµùë∑ùëΩ=# ùëúùëì ùëáùëüùë¢ùëí ùëÅùëíùëîùëéùë°ùëñùë£ùëí  ùëÜùëùùëíùëêùëñùëöùëíùëõùë†
# ùëúùëì ùëáùëüùë¢ùëí ùëÅùëíùëîùëéùë°ùëñùë£ùëí  ùëÜùëùùëíùëêùëñùëöùëíùëõùë† +# ùëúùëì ùêπùëéùëôùë†ùëí ùëÅùëíùëîùëéùë°ùëñùë£ùëí  ùëÜùëùùëíùëêùëñùëöùëíùëõùë† 
 
These rates will be reported along with exa ct two -sided 95% confidence intervals.  
 
OncoNano Medicine, Inc  
Study Protocol: O N-1005  Page 39 of 48 
Version 02 25 Jan 2022  Confidential  9.5 Quantification of Fluorescence Intensity  
Specimen -to-background (SBR) ratios  and tumor -to-background (TBR) ratios  will also be 
calculated using white light and NIR images of both SOC and pegsitacianine  guided specim ens. 
SBRs will be calculated using ex situ  images of collected specimens. The equation for calculating 
SBR is listed below.   
ùë∫ùë©ùëπ=ùëÄùëíùëéùëõ ùêπùëôùë¢ùëúùëüùëíùë†ùëêùëíùëõùëêùëí  ùêºùëõùë°ùëíùëõùë†ùëñùë°ùë¶  (ùëÜùëùùëíùëêùëñùëöùëíùëõ )
ùëÄùëíùëéùëõ ùêπùëôùë¢ùëúùëüùëíùë†ùëêùëíùëõùëêùëí  ùêºùëõùë°ùëíùëõùë†ùëñùë°ùë¶ (ùëÅùëúùëüùëöùëéùëô ùëáùëñùë†ùë†ùë¢ùëí)
TBR is calculated in the same way, but refers specifically to samples that are histologically 
confirmed as tumor.  
The mean fluorescence intensity of the specimen, of the background, and the SBR (or TBR) of 
each specimen will be summarized by the histologically -confirmed tumor status (either ‚Äútumor 
present‚Äù or ‚Äútumor not present/normal tissue‚Äù).  
9.6 Diagnostic Imaging Sen sitivity Analyses  
In this pilot study we are assuming that any fluorescence is indicative of tumor presence. To assess 
how the amount of observed fluorescence (e.g., the SBR or TBR) may affect the diagnostic 
accuracy of pegsitacianine, a receiver operating  characteristic (ROC) analysis will be performed 
on all specimens using the observed thresholds of SBR and TBR. The corresponding ROC curve 
will be provided along with the area under the curve (AUC).  
There is potential for within -subject correlation to bias  our estimates of pegsitacianine‚Äôs 
diagnostic accuracy. To assess this issue, an ROC curve will be constructed from a mixed model 
that clusters specimens by the subject they originated from. We will compare the AUC of the 
mixed effects ROC curve to the standard ROC curve to assess if within -subject correlation is 
causing significant bias in our analyses. If it is determined that significant bias has been 
introduced, additional analyses on secondary en dpoints may be performed to assess the 
diagnostic accuracy of pegsitacianine.  
9.7 Safety Analysis  
Safety data will be summarized by treatment group with descriptive statistics and frequency 
tables. In general, continuous data will be summarized by presenting the number of patients , 
mean, standard deviation, median, minimum, and maximum values. Categorical data will be 
summarized by presenting the number (frequency) and percentage of patients  at each level of 
response. Subject disposition will be presented and summarized.  
OncoNano Medicine, Inc  
Study Protocol: O N-1005   Page 40 of 48 
Version 02 25 Jan 2022  Confidential  Adverse events will be coded using MedDRA, Version 24.0 or higher , by system organ class and 
preferred term , and a listing of all AEs will be generated. Treatment -emergent AEs (TEAEs) , 
treatment -related TEAEs, TEAEs by intensity, TEAEs that lea d to discontinuation of study drug, 
and SAEs  will be summarized by treatment, system organ class, and preferred term.  
The clinical laboratory data will be  summarized by time point , treatment group, and change from 
baseline. The values that are below the lo wer limit or above the upper limit of the reference 
range will be  flagged. Those values or changes in values that are considered  clinically significant 
by the investigator will also be flagged.  Repeated or unscheduled results will not be included in 
the su mmary statistics but will be included in the individual data listings.  
9.8 Interim Analyses  
A single, internal interim analysis may occur after approximately 10 patients have been enrolled 
in an effort to better understand the feasibility and benefit of pegsit acianine imaging during lung 
malignancy resections. All analyses described herein will be conducted and evaluated by the 
sponsor. After an overall review of the data, a decision will be made by the sponsor to continue 
or terminate enrollment based on the i nterim findings. The Interim analys es will assess the utility 
of pegsitacianine based on mean fluorescence intensity analysis, calculation of tumor to 
background ratios, calculation of sensitivity and specificity, safety, and investigator feedback.  
The dec ision to continue or terminate is not based off of any individual endpoint and does not 
correspond to any collection of statistical tests, but instead a synthesis of all available 
information.  
 
10. DATA HAN DLING A ND QU ALITY ASSURAN CE 
10.1 Data Security  
The study da ta will be collected electronically. This electronic data capture (EDC) system 
complies with ICH GCP,  GDPR, and the current 21 CFR Part 11 guidance, Electronic Records 
and Signatures.  
10.2 Case Report Forms  
As part of the responsibilities assumed by participati ng in the study, the principal investigator 
agrees to maintain adequate case histories for the patients  treated as part of the research under 
this protocol. The principal investigator agrees to maintain accurate eCRFs and  source 
documentation as part of the case histories.  
MedTrials Inc.  will supply the eCRF. All eCRF information is to be filled in. If an item is not 
available or is not applicable, this fact will be indicated.  The eCRF has an electronic audit trail so 
changes can be made until the investigator signs the eCRF.  Each completed eCRF must be 
reviewed, signed, and dated by the principal investigator at the completion of the study . The 
completed eCRF will be collected by study monitors as soon as practical after completion. One 
copy will remain  at the site in the principal investigator‚Äôs files.  
10.3 Monitoring of the Study  
OncoNano Medicine, Inc  
Study Protocol: O N-1005   Page 41 of 48 
Version 02 25 Jan 2022  Confidential  The clinical monitor, as a representative of MedTrials Inc. and/or OncoNano Medicine, has the 
obligation to follow the study closely. In doing so, t he monitor will visit the principal 
investigator and study facility at periodic intervals, in addition to maintaining necessary contact 
through telephone, email, and letter. The monitor will maintain current personal knowledge of 
the study through observat ion, review of study records and source documentation, and discussion 
of the conduct of the study with the principal investigator and staff.  
All aspects of the study will be carefully monitored, by MedTrials Inc., OncoNano  Medicine  or a 
designee, for compliance with applicable government regulation with respect to current 
International Conference on Harmonisation (ICH) harmonised tripartite guideline E6(R1): Good 
Clinical Practice and current standard operating procedures.  
10.4 Inspection of Records  
The principal investigator and institutions involved in the study will permit trial -related 
monitoring, audits , institutional review board ( IRB) review, and regulatory inspection(s) by 
providing direct access to all study records. In the event o f an audit, the principal investigator 
agrees to allow MedTrials Inc., OncoNano Medicine, representatives of OncoNano Medicine,  
the United States Food and Drug Administration ( FDA ), and/or other regulatory agency access to 
all study records.  
The principal investigator should promptly notify  MedTrials and  OncoNano Medicine  of any 
audits scheduled by any regulatory authorities and promptly forward copies of any audit reports 
received to MedTrials Inc. and OncoNano Medicine . 
10.5 Study Record Retention  
Essential do cuments should be retained until at least 2 years after the last approval of a 
marketing application in an ICH region and until there are no pending or contemplated marketing 
applications in an ICH  region or at least 2 years have elapsed since the formal d iscontinuation of 
clinical development of the investigational product. These documents should be retained for a 
longer period, however, if required by the applicable regulatory requirements or by an agreement 
with MedTrials Inc. and/or OncoNano Medicine . It is the responsibility of MedTrials Inc. and 
OncoNano Medicine to inform the principal investigator as to when these documents no longer 
need to be retained.  
11. ADMINISTRATIVE CONSI DERATIONS  
The following administrative items are meant to guide the principal  investigator in the conduct of 
the trial but may be subject to change based on industry and government standard operating 
procedures or working practice documents or guidelines. Administrative changes will be 
reported to the IRB but will not result in pro tocol amendments.  
11.1 Confidentiality  
All laboratory specimens, evaluation forms, reports, and other records will be identified in a 
manner designed to maintain subject confidentiality. All records will be kept in a secure storage 
area with limited access. Cli nical information will not be released without the written permission 
OncoNano Medicine, Inc  
Study Protocol: O N-1005   Page 42 of 48 
Version 02 25 Jan 2022  Confidential  of the subject (or the subject‚Äôs guardian ), except as necessary for monitoring and auditing by 
OncoNano Medicine , its designee, the FDA, or the IRB.  
The principal investigator and all em ployees and coworkers involved with this study may not 
disclose or use for any purpose other than performance of the study, any data, record, or other 
unpublished, confidential information disclosed to those individuals for the purpose of the study. 
Prior written agreement from OncoNano Medicine or its designee must be obtained for the 
disclosure of any said confidential information to other parties.  
11.2 Institutional Review Board/Ethics Committee Approval  
Federal regulations and the ICH guidelines require that  approval be obtained from an IRB before  
participation of human patients  in research studies. Before  the study onset, the protocol, 
informed consent, advertisements to be used for subject recruitment, and any other written 
information regarding this study to be provided to the subject or the subject‚Äôs legal guardian 
must be approved by the IRB. Documentation of all IRB approvals and of the IRB compliance 
with ICH E6 (R1) will be maintained by the site and will be available for review by OncoNano 
Medicine  or its designee.  
All IRB approvals should be signed by the IRB chairman or designee and must identify the IRB 
name and address, the clinical protocol by title and/or protocol number and the date approval 
and/or favorable opinion was granted.  
The principal investigator is responsible for obtaining continued review of the clinical research at 
intervals not exceeding 1 year or otherwise specified by the IRB. The principal investigator must 
supply OncoNano Medicine or its designee with written doc umentation of continued review of 
the clinical research.  
11.3 Modification of the Protocol  
Any changes in this research activity, except those necessary to remove an apparent, immediate 
hazard to the subject, must be reviewed and approved by OncoNano Medicine o r its designee. 
Amendments to the protocol must be submitted in writing to the principal investigator‚Äôs IRB for 
approval before  patients  are enrolled into an amended protocol.  
11.4 Informed Consent  
A written informed consent in compliance with Part 50 of Title 21 of the Code of Federal 
Regulations ( CFR) shall  be obtained from each subject before entering the study or performing 
any unusual or nonroutine procedure that involves risk to the subject. An informed consent 
template may be provided by OncoNano Medicine  to investigative sites. If any institution -
specific modifications to study -related procedures are proposed or made by the site, the consent 
should be reviewed by OncoNano Medicine  and/or its designee, if appropriate , before  IRB 
submission. Once reviewed, the consent will be submitted by the principal investigator to their 
IRB for  review and approval before the start of the study. If the informed consent form is revised 
during the course of the study, all active participating patients  must sign the IRB -approved 
revised form.  
OncoNano Medicine, Inc  
Study Protocol: O N-1005   Page 43 of 48 
Version 02 25 Jan 2022  Confidential  Before recruitment and enrollment, each prospective subject will be given a full explanation of 
the study and allowed to read the approved informed consent form. Once the principal 
investigator is assured that the subject understands the  implications of participating in the study, 
the subject will be asked to give consent to participate in the study by signing the informed 
consent form.  
The principal investigator shall provide a copy of the original form of the signed informed 
consent to the subject and/or legal guardian.  
11.5 Protocol Violations and Deviations  
The principal investigator or designee must document and explain in the subject‚Äôs source 
documentation any deviation from the approved protocol. The principal investigator may 
implement  a deviation from or a change of  the protocol to eliminate an immediate hazard to trial 
patients  without prior IRB approval. As soon as possible after such an occurrence, the 
implemented deviation or change, the reasons for it, and any proposed protocol am endment(s) 
should be submitted to the IRB for review and approval, to OncoNano Medicine  for agreement, 
and to the regulatory authorities, if required.  
A deviation from the protocol is an unintended and/or unanticipated departure from the 
procedures and/or processes approved by OncoNano Medicine  and the IRB and agreed  to by the 
principal investigator. Deviations usually have an impact on individual patients  or a small group 
of patients  and do not involve inclusion/exclusion or primary endpoint criteria. A pr otocol 
violation occurs when there is nonadherence to the protocol that results in a significant, 
additional risk to the subject, when the subject or principal investigator has failed to adhere to 
significant protocol requirements (inclusion/exclusion crit eria) and the subject is enrolled 
without prior approval by OncoNano Medicine , or when there is nonadherence to FDA 
regulations and/or ICH  E6(R1)  guidelines.  
The clinical monitor will document protocol violations and deviations throughout the course of 
monitoring visits. The monitor will no tify the principal investigator  during a visit and/or in 
writing of all violations and deviations. The IRB should be notified of all protocol violations and 
deviations in a timely manner.  
11.6 Study Reporting Requirements  
By participating in this study, the principal investigator agrees to submit reports of SAEs 
according to the timeline and method outlined in the protocol. In addition, the principal 
investigator agrees to submit annual reports to their IRB as appropriate. The principal 
investigator also agrees to provide OncoNano Medicine  with an adequate report shortly after 
completion of the principal investigator‚Äôs participation in the study . 
11.7 Investigator Documentation  
Before beginning the study, the principal investigat or will be asked to comply with ICH 
E6(R1)  8.2 and 21 CFR by providing  the following essential documents, including but not 
limited to:  
ÔÇ∑ An original investigator -signed Investigator Agreement page of the protocol.  
OncoNano Medicine, Inc  
Study Protocol: O N-1005   Page 44 of 48 
Version 02 25 Jan 2022  Confidential  ÔÇ∑ An IRB -approved informed consent, samples of site advertisements for 
recruitment for this study, and any other written information regarding this study 
that is to be provided to the subject or legal guardians . 
ÔÇ∑ IRB approval . 
ÔÇ∑ Form FDA 1572, fully executed, and all updates o n a new fully executed For m 
FDA  1572 . 
ÔÇ∑ Curriculum vitae (CV) for the principal investigator and sub -investigators  listed 
on Form FDA 1572. Current licensure must be noted on the CV. They will be 
signed and date d by the principal investigator  at study start -up, indicating that 
they a re accurate and current . 
ÔÇ∑ Financial disclosure information to allow OncoNano Medicine  to submit 
complete and accurate certification or disclosure statements required under 21 
CFR  54. In addition, the investigators must provide to OncoNano Medicine  a 
commitment to promptly update this information if any relevant changes occur 
during the course of the investigation and for 1 year following the completion of 
the study . 
ÔÇ∑ Laboratory certifications and reference ranges for any local laboratories used by 
the site, in accordance with 42 CFR  493. 
11.8 Study Conduct  
The principal investigator agrees that the study will be conducted according to the principles of 
the ICH E6 (R1) guidelines and the principles of the World Medical Association Declaration of 
Helsinki. T he principal investigator will conduct all aspects of this study in accordance with all 
national, state, and local laws or regulations.  
11.9 Publications  
Following completion of the study, the data may be considered for reporting at a scientific 
meeting or for publication in a scientific journal. In these cases, OncoNano Medicine will be 
responsible for these activities and will work with the investigators to determine how the 
manuscript is written and edited, the number and order of authors, the publication to which it will 
be submitted, and other related issues. OncoNano Medicine has final approval authority over all 
such issues.  
Data are the property of OncoNano Medicine and cannot be published without prior 
authorization, but data and publication thereof will  not be unduly withheld.  
OncoNano Medicine, Inc  
Study Protocol: O N-1005   Page 45 of 48 
Version 02 25 Jan 2022  Confidential  12.  REFERENCES  
 
1 Society, A. C. Cancer Facts & Figures 2016. (American Cancer Society, Atlanta, 2016).  
2 Jemal, A.  et al.  Cancer statistics, 2009. CA Cancer J Clin  59, 225 -249, 
doi:10.3322/caac.20006 (2009).  
3 Aliperti, L. A., Predina, J. D., Vachani, A. & Singhal, S. Local and systemic recurrence is 
the Achilles heel of cancer surgery. Ann Surg Oncol  18, 603 -607, doi:10.1245/s10434 -
010-1442 -0 (2011).  
4 Ma, X.  et al.  Ultra -pH-sensitive nanoprobe library with broad p H tunability and 
fluorescence emissions. J Am Chem Soc  136, 11085 -11092, doi:10.1021/ja5053158 
(2014).  
5 Zhao, T.  et al.  A Transistor -like pH Nanoprobe for Tumour Detection and Image -guided 
Surgery. Nat Biomed Eng  1, doi:10.1038/s41551 -016-0006 (2016).  
6 Li, Y. et al.  Molecular basis of cooperativity in pH -triggered supramolecular self -
assembly. Nat Commun  7, 13214, doi:10.1038/ncomms13214 (2016).  
7 Voskuil, F. J.  et al.  Exploiting metabolic acidosis in solid cancers using a tumor -agnostic 
pH-activatable na noprobe for fluorescence -guided surgery. Nat Commun  11, 3257, 
doi:10.1038/s41467 -020-16814 -4 (2020).  
 
 
OncoNano Medicine, Inc  
Study Protocol: O N-1005  Page 47 of 48 
Version 02 25 Jan 2022  Confidential  Footnotes  
a For female patients , a serum  sample or urine dipstick for a  pregnancy test will be collected at screening and on Day 0 and Day 21 . 
b Body mass index will be calculated at Screening only.  
c Vital sign measurements will include systolic and diastolic blood pressure, pulse, respiratory rate, and temperature  (in degrees Cels ius). Blood pressure and 
pulse will be measured after a resting period of at least 5  minutes in the supine position . 
d Patient‚Äôs vital signs are to  be recorded immediately after the infusion and 30 minutes afterward  
e The Sponsor recommends the use of prophylactic diphenhydramine prior to study drug administration, in an effort to reduce the  prevalence of infusion -related 
reactions.    
f Patients  will be assessed for AEs occurring from the time of dosing through Day 2 1 (¬±10 days)   
g Hematology assessments may include  hemoglobin , hematocrit , erythrocyte count (red blood cells) , differential leukocytes , platelet count , and t otal leukocytes 
(white bl ood cells) . 
h Pathologic analysis of surgical specimens will take place from the conclusion of surgery and up to 10 days after  
 
OncoNano Medicine, Inc  
Study Protocol: O N-1005  Page 48 of 48 
Version 02 25 Jan 2022  Confidential  14. APPENDIX 2: FDA -CLEARED NIR IMAGI NG DEVICES  
NOTE:  this list is not comprehensive and does not restrict the use of other FDA -cleared imaging 
device from use in this trial.  
14.1 NOVADAQ SPY  Elite  
The NOVADAQ SPY  Elite system is an active device used for intraoperative fluorescence 
imaging. The device is developed for open surgery. The device uses visible (white light) and NIR 
spectra in real -time to visualize circulation and ICG based tumor detection. The device is 
commerciall y available and 510(k) cleared by the FDA  for surgical use . 
14.2 NOVADAQ SPY -PHI 
The NOVADAQ SPY -PHI (Portable Handheld Imaging) system is an active device used for 
fluorescence imaging. The device uses both visible (white light) and NIR spectra , which can be 
used for visualization of circulation and ICG -based tumor detection during several (surgical or 
non-surgical) procedures. The device is commercially available and 510(k) cleared by the FDA  
for surgical use . 
14.3 NOVADAQ PIN POIN T 
The NOVADAQ PINPOINT is an intrao perative laparoscopic fluorescence imaging system, used 
in conjunction with an injected ICG based fluorescent imaging agent, to assess perfusion and 
visualize structural anatomy using visible (white light) and NIR during cardiothoracic, 
gastrointestinal, b reast, and other reconstructive surgical procedures.  
14.4 da Vinci Firefly  
The da Vinci Firefly system (Intuitive Surgical, California, USA) provides real -time NIR guidance 
through visualization of injectable fluorescence dye.  The device uses visible (white li ght) and NIR 
spectra in real -time to visualize circulation and ICG based tumor detection. The device is 
commercially available and FDA -cleared for visual assessment of vessels, blood flow , and related 
tissue perfusion using NIR imaging .  
14.5 Vision sense Iridiu m 
The Visionsense Iridium camera system (Visionsense, Philadelphia, PA, USA ) uses 3DHD 
technology intra -operatively for real -time infrared fluorescence and white light imaging 
visualization during live surgery to enhance anatomical feature identification.  
 